Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10836772
DNA polymerase IIIC inhibitors and use thereof
granted -
US 10836789
Inhibitors of glucocorticoid receptor
granted -
US 10836827
Antibodies specific to glycosylated PD-L1 and methods of use thereof
granted -
US 10837016
Modulation of huntingtin expression
granted -
US 10835487
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 10835490
Solid solution compositions and use in chronic inflammation
granted -
US 10835513
Methods and treatments for the learning and memory deficits associated with Noonan syndrome
granted -
US 10835593
Modified anthrax toxin protective antigen
granted -
US 10835604
Biomaterials for combined radiotherapy and immunotherapy of cancer
granted -
US 10835755
Method of using laser-induced optoacoustics for the treatment of drug-resistant microbial infections
granted -
US 10836741
Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
granted -
US 10835514
Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
granted -
US 10836759
Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer
granted -
US 10837961
Molecular imprinted colored silica beads
granted -
US 10836763
5 to 7 membered heterocyclic amides as JAK inhibitors
granted -
US 10837003
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
granted -
US 10837019
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10835495
Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
granted -
US 10835505
Oral pharmaceutical formulation for weight loss, diabetes and related disorders
granted -
US 10835517
Methods for treating ocular demodex using isoxazoline parasiticide formulations
granted -
US 10835503
Pre-filled syringe
granted -
US 10835541
Tablet
granted -
US 10844076
Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
granted -
US 10844090
Hemiasterlin derivatives for conjugation and therapy
granted -
US 10842980
Systems, devices, and/or methods for managing transdermal patches
granted -
US 10842737
Vaginal probiotic products and related processes
granted -
US 10842908
Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use
granted -
US 10845366
Predictive markers for polyamine inhibitor cancer therapies
granted -
US 10842743
Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
granted -
US 10842664
Skin-like condoms having active ingredients to enhance a male erection and a female arousal
granted -
US 10842814
Use of low dose arsenic for preserving genomic integrity
granted -
US 10842791
Small molecule inhibitors of EGFR and PI3K
granted -
US 10842826
Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
granted -
US 10842823
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
granted -
US 10842801
Optimizing mifepristone absorption
granted -
US 10844137
Anti-CTLA-4 antibodies and uses thereof
granted -
US 10844387
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 10844058
Valbenazine salts and polymorphs thereof
granted -
US 10844064
sGC stimulators
granted -
US 10842800
Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
granted -
US 10844040
Nrf2 activating compounds and uses thereof
granted -
US 10842835
Oncolytic vaccinia virus mutants and using same for cancer treatment
granted -
US 10844052
LLS compounds for treatment of cancer
granted -
US 10844098
Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use of the protein
granted -
US 10844102
Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
granted -
US 10844129
Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids
granted -
US 10844353
Methods for preparing therapeutically active cells using microfluidics
granted -
US 10844357
Engineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.